Diagnostic and prognostic significance of measuring antibodies to α-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren's syndrome

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 845-849

  Locht, Henning ^a   Pelck, Randi ^a   Manthorpe, Rolf ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b Sjogren's Syndrome Research Centre   (Sweden)

Author keywords

anti fodrin; anti La; anti Ro 52; anti Ro 60; Primary Sj gren's syndrome

Indexed keywords

AUTOANTIBODY; FODRIN ALPHA ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LA ANTIBODY; RECOMBINANT PROTEIN; RO 52 ANTIBODY; RO 60 ANTIBODY;

ARTICLE; CAUCASIAN; CLINICAL EXAMINATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; HEMATOLOGIC DISEASE; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME;

ANTIBODIES; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CARRIER PROTEINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROFILAMENT PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME;

EID: 44349162989     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjogren's syndrome. Clin Exp Immunol 1998;114:485-90.
2. Asmussen K, Andersen V, Bendixen G, et al. Quantitative assessment of clinical disease status in primary Sjogren's syndrome. A cross-sectional study using a new classification model. Scand J Rheumatol 1997; 26:197-205.
3. Harley JB, Alexander EL, Bias WB, et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome. Arthritis Rheum 1986;29:196-206.
4. Price EJ, Venables PJ. The etiopathogenesis of Sjogren's syndrome. Semin Arthritis Rheum 1995;25:117-33.
5. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
6. Haneji N, Nakamura T, Takio K, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 1997;276:604-7.
7. Witte T, Matthias T, Arnett FC, et al. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren's syndrome. J Rheumatol 2000;27:2617-20.
8. Maeno N, Takei S, Imanaka H, et al. Anti-alpha-fodrin antibodies in Sjogren's syndrome in children. J Rheumatol 2001;28:860-4.
9. Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K. Anti-alpha-fodrin antibodies in Sjogren syndrome and lupus erythematosus. Arch Dermatol 1999;135:535-9.
10. Nordmark G, Rorsman F, Ronnblom L, et al. Autoantibodies to alpha-fodrin in primary Sjogren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol 2003;21:49-56.
11. Ruffatti A, Ostuni P, Grypiotis P, et al. Sensitivity and specificity for primary Sjogren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA. J Rheumatol 2004;31:504-7.
12. Manthorpe R, Oxholm P, Prause JU, Schiodt M. The Copenhagen criteria for Sjogren's syndrome. Scand J Rheumatol Suppl 1986;61:19-21.
13. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
14. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986;189:113-30.
15. Miller LK. Baculoviruses as gene expression vectors. Annu Rev Microbiol 1988;42:177-99.
16. Bizzaro N, Bonelli F, Tonutti E, Tozzoli R, Villalta D. New coupled-particle light-scattering assay for detection of Ro/SSA (52 and 60 kilodaltons) and La/SSB autoantibodies in connective tissue diseases. Clin Diagn Lab Immunol 2001;8:922-5.
17. Halse AK, Marthinussen MC, Wahren-Herlenius M, Jonsson R. Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjogren's syndrome. Scand J Rheumatol 2000;29:13-9.
18. Salomonsson S, Wahren-Herlenius M. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjogren's syndrome. Scand J Rheumatol 2003;32:79-82.
19. Pourmand N, Wahren-Herlenius M, Gunnarsson I, et al. Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 1999;58:623-9.
20. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004;50:882-91.
21. Itoh Y, Itoh K, Frank MB, Reichlin M. Autoantibodies to the Ro/SSA autoantigen are conformation dependent. II: Antibodies to the denatured form of 52 kD Ro/SSA are a cross-reacting subset of antibodies to the native 60 kD Ro/SSA molecule. Autoimmunity 1992;14:89-95.
22. Itoh Y, Reichlin M. Autoantibodies to the Ro/SSA antigen are conformation dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein. Autoimmunity 1992;14:57-65.
23. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
24. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
25. Ulbricht KU, Schmidt RE, Witte T. Antibodies against alpha-fodrin in Sjogren's syndrome. Autoimmun Rev 2003;2:109-13.
26. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
27. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.